Philip John Borsellino, Savannah Schauer, Axel Rivas, Karl Aharonian, Thomas A Vida
{"title":"填补盲点:将查尔斯·邦纳综合征筛查纳入眼科。","authors":"Philip John Borsellino, Savannah Schauer, Axel Rivas, Karl Aharonian, Thomas A Vida","doi":"10.2147/OPTH.S547122","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Charles Bonnet Syndrome (CBS) is an underdiagnosed condition affecting patients with significant vision loss who experience complex visual hallucinations while maintaining cognitive insight. This scoping review aims to synthesize existing literature on CBS prevalence, risk factors, and screening practices, and to propose a standardized, clinically implementable screening workflow for ophthalmologists.</p><p><strong>Patients and methods: </strong>We conducted a structured literature search across four databases (PubMed, Embase, Web of Science, Scopus) using keywords related to CBS, visual impairment, screening, and diagnosis. Inclusion criteria encompassed peer-reviewed studies involving patients with vision loss that reported the use of screening tools, diagnostic criteria, or clinical assessments of CBS. Excluded were case reports with fewer than five patients, articles lacking full text or peer review, and those focused primarily on psychiatric or neurologic hallucinations. We identified 1,582 articles, with 89 studies meeting the final inclusion criteria.</p><p><strong>Results: </strong>CBS prevalence ranged from 2% to 30%, depending on the underlying ocular condition and screening method used. Age-related macular degeneration showed the highest association. Few studies utilized validated screening tools though the QR-SCB and NEVHI instruments demonstrated clinical utility. Barriers to diagnosis included patient reluctance to report symptoms and clinician unfamiliarity. We developed a pragmatic clinical model incorporating risk stratification, direct questioning, validated tools, and functional assessment to improve detection in ophthalmology clinics.</p><p><strong>Conclusion: </strong>CBS remains underdiagnosed despite its significant psychosocial burden. A structured screening approach may increase diagnostic accuracy and support timely intervention. The proposed model offers ophthalmologists a practical pathway to integrate CBS assessment into routine care.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3619-3657"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502960/pdf/","citationCount":"0","resultStr":"{\"title\":\"Filling in the Blind Spot: Integrating Charles Bonnet Syndrome Screening in Ophthalmology.\",\"authors\":\"Philip John Borsellino, Savannah Schauer, Axel Rivas, Karl Aharonian, Thomas A Vida\",\"doi\":\"10.2147/OPTH.S547122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Charles Bonnet Syndrome (CBS) is an underdiagnosed condition affecting patients with significant vision loss who experience complex visual hallucinations while maintaining cognitive insight. This scoping review aims to synthesize existing literature on CBS prevalence, risk factors, and screening practices, and to propose a standardized, clinically implementable screening workflow for ophthalmologists.</p><p><strong>Patients and methods: </strong>We conducted a structured literature search across four databases (PubMed, Embase, Web of Science, Scopus) using keywords related to CBS, visual impairment, screening, and diagnosis. Inclusion criteria encompassed peer-reviewed studies involving patients with vision loss that reported the use of screening tools, diagnostic criteria, or clinical assessments of CBS. Excluded were case reports with fewer than five patients, articles lacking full text or peer review, and those focused primarily on psychiatric or neurologic hallucinations. We identified 1,582 articles, with 89 studies meeting the final inclusion criteria.</p><p><strong>Results: </strong>CBS prevalence ranged from 2% to 30%, depending on the underlying ocular condition and screening method used. Age-related macular degeneration showed the highest association. Few studies utilized validated screening tools though the QR-SCB and NEVHI instruments demonstrated clinical utility. Barriers to diagnosis included patient reluctance to report symptoms and clinician unfamiliarity. We developed a pragmatic clinical model incorporating risk stratification, direct questioning, validated tools, and functional assessment to improve detection in ophthalmology clinics.</p><p><strong>Conclusion: </strong>CBS remains underdiagnosed despite its significant psychosocial burden. A structured screening approach may increase diagnostic accuracy and support timely intervention. The proposed model offers ophthalmologists a practical pathway to integrate CBS assessment into routine care.</p>\",\"PeriodicalId\":93945,\"journal\":{\"name\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"volume\":\"19 \",\"pages\":\"3619-3657\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502960/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OPTH.S547122\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S547122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:查尔斯邦纳综合征(CBS)是一种未被诊断的疾病,影响严重视力丧失的患者,他们在保持认知洞察力的同时经历复杂的视觉幻觉。本综述旨在综合现有的关于CBS患病率、危险因素和筛查实践的文献,并为眼科医生提出一个标准化的、临床可实施的筛查工作流程。患者和方法:我们在四个数据库(PubMed、Embase、Web of Science、Scopus)中进行了结构化文献检索,使用与CBS、视力障碍、筛查和诊断相关的关键词。纳入标准包括同行评审的涉及视力丧失患者的研究,这些研究报告了使用筛查工具、诊断标准或CBS的临床评估。排除病例报告少于5名患者,缺乏全文或同行评议的文章,以及主要关注精神或神经幻觉的文章。我们确定了1582篇文章,其中89篇研究符合最终纳入标准。结果:CBS患病率从2%到30%不等,这取决于潜在的眼部状况和使用的筛查方法。年龄相关性黄斑变性的相关性最高。很少有研究使用经过验证的筛选工具,尽管QR-SCB和nehi仪器显示了临床实用性。诊断障碍包括患者不愿报告症状和临床医生不熟悉。我们开发了一种实用的临床模型,包括风险分层、直接询问、有效工具和功能评估,以提高眼科诊所的检测。结论:尽管CBS有严重的社会心理负担,但仍未得到充分诊断。结构化的筛查方法可以提高诊断的准确性并支持及时干预。提出的模型为眼科医生提供了将CBS评估纳入常规护理的实用途径。
Filling in the Blind Spot: Integrating Charles Bonnet Syndrome Screening in Ophthalmology.
Purpose: Charles Bonnet Syndrome (CBS) is an underdiagnosed condition affecting patients with significant vision loss who experience complex visual hallucinations while maintaining cognitive insight. This scoping review aims to synthesize existing literature on CBS prevalence, risk factors, and screening practices, and to propose a standardized, clinically implementable screening workflow for ophthalmologists.
Patients and methods: We conducted a structured literature search across four databases (PubMed, Embase, Web of Science, Scopus) using keywords related to CBS, visual impairment, screening, and diagnosis. Inclusion criteria encompassed peer-reviewed studies involving patients with vision loss that reported the use of screening tools, diagnostic criteria, or clinical assessments of CBS. Excluded were case reports with fewer than five patients, articles lacking full text or peer review, and those focused primarily on psychiatric or neurologic hallucinations. We identified 1,582 articles, with 89 studies meeting the final inclusion criteria.
Results: CBS prevalence ranged from 2% to 30%, depending on the underlying ocular condition and screening method used. Age-related macular degeneration showed the highest association. Few studies utilized validated screening tools though the QR-SCB and NEVHI instruments demonstrated clinical utility. Barriers to diagnosis included patient reluctance to report symptoms and clinician unfamiliarity. We developed a pragmatic clinical model incorporating risk stratification, direct questioning, validated tools, and functional assessment to improve detection in ophthalmology clinics.
Conclusion: CBS remains underdiagnosed despite its significant psychosocial burden. A structured screening approach may increase diagnostic accuracy and support timely intervention. The proposed model offers ophthalmologists a practical pathway to integrate CBS assessment into routine care.